Cirrhosis News and Research

Latest Cirrhosis News and Research

Study sheds light on mechanisms behind liver fibrosis and potential therapies

New research from the University of Pittsburgh School of Pharmacy sheds light on the processes that lead to liver fibrosis and suggests a novel treatment approach for this common and serious condition.

25 Sep 2024

Speech analysis phone app could identify early signs of hepatic encephalopathy

Research from the University of Michigan suggests that one day a phone app could be able to detect the development of hepatic encephalopathy in patients just by listening to them speak.

18 Sep 2024

Long-term exercise leads to healthier fat storage in obese individuals

People with obesity who are long-time exercisers have healthier belly fat tissue and can store fat there more effectively than nonexercisers with obesity, according to a new study from a team of researchers at the University of Michigan.

10 Sep 2024

Long-term air pollution exposure and poor lifestyle choices increase risk of non-alcoholic fatty liver disease

Long-term exposure to air pollution and poor lifestyle choices are key contributors to non-alcoholic fatty liver disease (NAFLD), affecting global liver health.

3 Sep 2024

Study reveals key role of A20 protein in controlling inflammation in liver disease

Many individuals worldwide suffer from chronic liver disease (CLD), which poses significant concerns for its tendency to lead to hepatocellular carcinoma or liver failure. CLD is characterized by inflammation and fibrosis.

29 Aug 2024

Understanding the mechanisms of cardiac fibrosis

The article explores the role of the m6A reader YTHDF1 in cardiac fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins, leading to the stiffening of the heart and impaired function. Cardiac fibrosis is a common pathological process in various cardiovascular diseases, including hypertension, myocardial infarction, and heart failure.

29 Aug 2024

New insights into macrophages' role in MASH and liver fibrosis

Formerly known as nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis (MASH) is an inflammatory disease characterized by liver scarring or fibrosis that progressively impairs liver function.

22 Aug 2024

Breakthrough treatment reduces liver fibrosis in Hepatitis C patients

HCV infection is the underlying cause for chronic Hepatitis C (CHC), liver cirrhosis, and liver cancer or hepatocellular carcinoma (HCC). In 2019, over 2,90,000 people died of HCV-related diseases. Recent medical advancement made a new breakthrough treatment available for patients with hepatitis C. DAAs that block replication of HCV has dramatically transformed the treatment approach with around 90% effective anti-viral response rates. However, it is unclear whether DAAs impact the severity of disease burden caused by liver fibrosis.

21 Aug 2024

Global and Local Efforts to Take Action Against Hepatitis

In this interview, we explore global and local efforts to combat viral hepatitis with Lindsey Hiebert, Deputy Director of the Coalition for Global Hepatitis Elimination (CGHE), and James Amugsi, a Mandela Washington Fellow and Physician Assistant at Sandema Hospital in Ghana. Together, they provide valuable insights into the challenges, successes, and the importance of partnerships in the fight against hepatitis.

20 Aug 2024

Stretching vs. meditation: New study finds both practices reduce nocturnal muscle cramps in cirrhosis patients

Researchers investigate the effects of stretching and meditation on nocturnal muscle cramps in patients with cirrhosis.

15 Aug 2024

Stretching and meditation ease nocturnal muscle cramps in cirrhosis patients

People suffering from cirrhosis may find some symptom relief from two accessible activities: stretching and meditation.

12 Aug 2024

The real cost of processed foods: How Western diets are harming global health

A recent study in Nature Medicine reviews the adverse effects of Western diets on human health, highlighting increased risks of chronic diseases and gut dysbiosis. Researchers call for global awareness and promotion of healthier dietary patterns.

6 Aug 2024

Review highlights the interplay of TGF-β and HIPPO pathways in liver regeneration and disease

The liver's ability to communicate with other organs is crucial for maintaining homeostasis, particularly through signaling pathways.

30 Jul 2024

Understanding the epigenetic regulation of hepatic stellate cells in NAFLD

Non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide, affecting approximately 38% of the global population from 2016 to 2019.

25 Jul 2024

New study helps better understand the pathology of fatty liver disease MASH

A new study brings researchers closer to better understanding the pathology of the fatty liver disease MASH, which stands for metabolic dysfunction-associated steatohepatitis.

24 Jul 2024

Stroop-CN: A rapid diagnostic tool for minimal hepatic encephalopathy

This study is led by Dr. Xiaolong Qi (Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology) and Dr. Junliang Fu (Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases).

19 Jul 2024

Navigating adjuvant therapy options in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths.

16 Jul 2024

Ultrasound techniques for the surveillance, diagnosis, and treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and one of the leading causes of cancer-related deaths worldwide. Early detection and accurate diagnosis are crucial for effective management and improved survival rates.

16 Jul 2024

Existing drug shows promise for treating common liver disease

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.

11 Jul 2024

Aging aggravates liver fibrosis in Down Syndrome, new study finds

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 12, entitled, "Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome."

10 Jul 2024